MicroRNA-9 regulates neural apoptosis in methylmalonic acidemia via targeting BCL2L11

作者：Li Yanfei; Peng Tao; Li Lin; Wang Xiaohan; Duan Ranran; Gao Huili; Guan Wenjuan; Lu Jingjing; Teng Junfang; Jia Yanjie^*

来源：International Journal of Developmental Neuroscience, 2014, 36(1): 19-24.

DOI：10.1016/j.ijdevneu.2014.04.005

• MicroRNA-9
• BCL2L11
• Apoptosis
• Methylmalonic acidemia

Methylmalonic acidemia (MMA) is an autosomal-recessive inborn metabolic disorder that results from a deficiency in methylmalonyl-coenzyme A mutase or its cofactor, adenosylcobalamin. Currently, neurological manifestations in MMA are thought to be associated with neural apoptosis. BCL2L11, which is a proapoptotic Bcl-2 family member, is resident in the outer mitochondrial membrane, where this protein acts as a central regulator of the intrinsic apoptotic cascade and mediates excitotoxic apoptosis. MicroRNAs (miRNAs) are a class of non-coding RNAs that function, as endogenous triggers of the RNA interference pathway. Currently, little is known regarding the role of miRNA in MMA. In our previous study, we preliminarily found that the expression of miR-9 was significantly down-regulated in MMA patient plasma and sensitively changed after VitB12 treatment, which may act as a potential "competitor" of gas chromatography-mass spectrometry for the diagnosis of MMA. In the present study, we first confirmed that miR-9 inhibited BCL2L11 expression by directly targeting its 3'-untranslated region, and the up-regulation of miR-9 reduced neural apoptosis induced by methylmalonate via targeting BCL2L11. Taken together, our results suggested that miR-9 might act as a monitor of changes in MMA and might provide new insights into a therapeutic entry point for treating MMA.

• 出版日期2014-8
• 单位郑州大学